Polypharmacy and hypertension: evaluating drug-drug interactions and the pharmacist’s role in risk reduction

Abstract

Introduction: Polypharmacy, as the co-administration of five or more drugs, is a common issue in hypertensive groups everywhere in the world, specifically in Ukraine and Eastern European countries, where there is a high occurrence of diffuse comorbidity (Diaconu C. et al., 2021; Hrebenyk M. et al., 2025). This is a multifacet- ed phenomenon that is also associated with high numbers of drug-drug and food-drug interactions, hence obscuring blood pressure control and aggravating adverse drug reactions risk (Zare P. et al., 2024). The impact of multimorbidity has a great capacity in elevating difficulties in pharmacotherapy in aged hypertensive groups everywhere in the world (Nicholson K. et al., 2024).